PT  - JOURNAL ARTICLE
AU  - HARUKA KANAOKA
AU  - MASAYUKI NAGAHASHI
AU  - YUSA ATAKE
AU  - AKIRA HATTORI
AU  - AYAKO BUN
AU  - REIKO FUKUI
AU  - HIROMI OZAWA
AU  - YUKIE FUJIMOTO
AU  - TOMOKO HIGUCHI
AU  - KEIKO NATORI
AU  - MICHIKO IMAMURA
AU  - KEIKO MURASE
AU  - YUICHI TAKATSUKA
AU  - YASUO MIYOSHI
TI  - Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors
AID  - 10.21873/anticanres.15992
DP  - 2022 Oct 01
TA  - Anticancer Research
PG  - 4867--4878
VI  - 42
IP  - 10
4099  - http://ar.iiarjournals.org/content/42/10/4867.short
4100  - http://ar.iiarjournals.org/content/42/10/4867.full
SO  - Anticancer Res2022 Oct 01; 42
AB  - Background/Aim: The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and C-reactive protein (CRP) in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer treated with the CDK4/6 inhibitors, abemaciclib and palbociclib. Patients and Methods: A total of 83 patients treated with fulvestrant plus abemaciclib or palbociclib were included in this study. Progression-free survival (PFS) and overall survival (OS) were compared in relation to baseline levels of ALC, NLR, PLR and CRP. Results: The cut-off values of ALC, NLR, PLR, and CRP for PFS were determined from the receiver operating characteristic curve using the Youden index for area under the curve and set at 1,212/μl, 1.964, 170 and 0.220 mg/dl, respectively. In the abemaciclib-treated group, ALC-high patients showed significantly better PFS than ALC-low patients (p=0.0151) and multivariate analysis revealed that ALC was an independent prognostic factor for PFS (p=0.0085). In the palbociclib-treated group, there was no significant relationship between any peripheral blood biomarkers and PFS. In both treatment groups, ALC-high patients showed significantly better OS than ALC-low patients (p=0.0169 and 0.0290, respectively). Multivariate analysis revealed ALC was an independent prognostic factor for OS in both abemaciclib- and palbociclib-treated groups (p=0.0112 and 0.0202, respectively). Conclusion: ALC is an independent prognostic factor for estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer patients treated with the CDK4/6 inhibitors abemaciclib and palbociclib.